Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03018392
Other study ID # TRITANIUM
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 2017
Est. completion date January 28, 2020

Study information

Verified date August 2022
Source Bone and Joint Clinic of Baton Rouge
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the fusion rate and clinical outcomes at 1 year of 20 patients with degenerative disc disease who undergo a Transforaminal Lumbar Interbody Fusion (TLIF) with the Stryker Tritanium Spinal System. This is an on-label, post-market outcomes study to build on the body of long-term evidence for the device.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date January 28, 2020
Est. primary completion date January 28, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subject has one or more of the following diagnoses: degenerative disc disease (DDD) at one level or two contiguous levels from L2 to S1, and may also include up to Grade I spondylolisthesis at the involved level(s); degenerative scoliosis for which the Tritanium PL cage will be used as an adjunct to fusion - Skeletally mature and = 18 years old at time of enrollment - Completed at least 6 months of non-operative therapy prior to surgery - Willing and able to sign a study specific consent and comply with the requirements of the protocol including follow up visits and imaging. Exclusion Criteria: - 2 levels requiring surgical intervention - Non-degenerative pathology including tumor, trauma, post-laminectomy kyphosis - Psudeoarthrosis at the index level - Previous fusion at the levels to be treated or at adjacent level - Any abnormality present which affects the normal process of bone remodeling including, but not limited to, severe osteoporosis involving the spine, bone absorption, osteopenia, primary or metastatic tumors involving the spine, active infection at the site or certain metabolic disorders affecting osteogenesis. - History of osteoporotic fracture - History of an endocrine or metabolic disorder known to affect bone and mineral metabolism - Inadequate tissue coverage over the operative site or taking medications that may interfere with bony/soft tissue healing including chronic steroid use - Known allergy to titanium or cobalt chrome or may be sensitive to materials - Rheumatoid arthritis or other autoimmune disease or a systemic disorder such as HIV, active hepatitis B or C or fibromyalgia - Lumbar kyphosis- lumbar lordosis < 20° - Degenerative scoliosis >20° OR any other pathology scoliosis (idiopathic, congenital, posttraumatic, iatrogenic) - Active systemic infection or infection at the operative site - Marked local inflammation - Any open wounds - Pregnant, or intends to become pregnant during the study - Current smokers - Subject is class 3 obese (BMI >40) or overweight and can produce loads on the spinal system which can lead to failure of the fixation of the device or to failure of the device itself - Any mental or neuromuscular disorder which would create an unacceptable risk of fixation failure or complications in postoperative care - Any neuromuscular deficit which places an unsafe load level on the device during the healing period - Any other medical or surgical condition which would preclude the potential benefit of spinal implant surgery, such as the presence of tumors, congenital abnormalities, elevation of sedimentation rate unexplained by other diseases, elevation of white blood cell count (WBC), or marked left shift in the WBC differential count. - Any condition of senility, mental illness, or substance abuse. - Involved in current spinal litigation that may interfere or influence patient self-assessment of function and pain - Physical or mental condition that may interfere or influence patient self-assessment of function and pain. - Incarcerated at the time of study enrollment

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Stryker Tritanium Spinal System
open transforaminal lumbar interbody fusion (TLIF) utilizing the Stryker Tritanium cages with pedicle screw fixation according to instructions for use and package labeling for on-label indications

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Bone and Joint Clinic of Baton Rouge

Outcome

Type Measure Description Time frame Safety issue
Primary Fusion Rate Fusion status at 1 year post-operatively was graded as - fused (best outcome), progressing, or pseudoarthrosis (failed fusion) 1 year
See also
  Status Clinical Trial Phase
Completed NCT01941563 - A Study of SI-6603 in Patients With Lumbar Disc Herniation Phase 3
Completed NCT02931279 - PASS OCT® Post-market Clinical Follow-up
Completed NCT02225444 - A Prospective Study of Instrumented, Posterolateral Lumbar Fusions (PLF) With OsteoAMP®
Completed NCT02421601 - A Study of SI-6603 in Patients With Lumbar Disc Herniation Phase 3
Terminated NCT02381067 - A Prospective Study of NuCel® in Cervical Spine Fusion N/A
Completed NCT01860417 - Treatment of Degenerative Disc Disease With Allogenic Mesenchymal Stem Cells (MSV) Phase 1/Phase 2
Completed NCT01513694 - Clinical Trial Based on the Use of Mesenchymal Stem Cells From Autologous Bone Marrow in Patients With Lumbar Intervertebral Degenerative Disc Disease Phase 1/Phase 2
Completed NCT02023372 - Efficacy Study of NuCel® in Patients Undergoing Fusion of the Lumbar Spine N/A